(4) Single route of administration: the current preclinical animal studies and clinical human trials predominantly employ oral administration as the primary intervention method for BBR, with a notable lack of research on alternative delivery approaches such as transdermal absorption
A recent meta-analysis of randomized trials in obesity and/or diabetes found no increased risk of psychiatric adverse events, with improvements in quality of life, restrained eating, and emotional regulation measures (204)
Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results
PT-141 - Intensify sexual desire & function
With regular glutathione IV therapy, you not only cleanse your system but also reduce oxidative stress, a major factor in premature aging
